HLA-DR3
{{cs1 config|name-list-style=vanc}}
| id="drugInfoBox" style="float: right; clear: right; margin: 0 0 0.5em 1em; background: #ffffff;" class="toccolours" border=0 cellpadding=0 align=right width="240px" | |
| align="center" colspan="3" | Image:DR Illustration.PNG | |
| align="center" colspan="2" | | |
| align="center" colspan="2" | major histocompatibility complex, class II, DR3 | |
| bgcolor="#e7dcc3" | Haplotypes groups
| bgcolor="#eeeeee" | DRA*01:DRB1*03:01 DRA*01:DRB1*03:02 DRA*01:DRB1*03:03 DRA*01:DRB1*03:04 | |
| colspan="2" bgcolor="#dddddd" | Structure (See HLA-DR) | |
| style="background:#f8f8f8"
| bgcolor="#dddddd" | Identifiers | align="center" | alpha *01:01 |
| bgcolor="#e7dcc3" | Symbol(s)
| bgcolor="#eeeeee" | [http://www.gene.ucl.ac.uk/nomenclature/data/get_data.php?hgnc_id=HGNC4947 HLA-DRA]{{Dead link|date=October 2019 |bot=InternetArchiveBot |fix-attempted=yes }} | |
| bgcolor="#e7dcc3" | EBI-HLA
| bgcolor="#eeeeee" | [http://www.ebi.ac.uk/cgi-bin/imgt/hla/get_allele.cgi?DRA*0101 DRA*01:01] | |
| style="background:#f8f8f8"
| bgcolor="#dddddd" | Identifiers | align="center" | beta 1 *03:01 *03:01 *03:02 *03:03 *03:04 |
| bgcolor="#e7dcc3" | Symbol(s)
| bgcolor="#eeeeee" | [http://www.gene.ucl.ac.uk/nomenclature/data/get_data.php?hgnc_id=4953 HLA-DRB1]{{Dead link|date=October 2019 |bot=InternetArchiveBot |fix-attempted=yes }} | |
| bgcolor="#e7dcc3" | EBI-HLA
| bgcolor="#eeeeee" | [http://www.ebi.ac.uk/cgi-bin/imgt/hla/get_allele.cgi?DRB1*0301 DRB1*03:01] | |
| bgcolor="#e7dcc3" | EBI-HLA
| bgcolor="#eeeeee" | [http://www.ebi.ac.uk/cgi-bin/imgt/hla/get_allele.cgi?DRB1*0302 DRB1*03:02] | |
| bgcolor="#e7dcc3" | EBI-HLA
| bgcolor="#eeeeee" | [http://www.ebi.ac.uk/cgi-bin/imgt/hla/get_allele.cgi?DRB1*0303 DRB1*03:03] | |
| bgcolor="#e7dcc3" | EBI-HLA
| bgcolor="#eeeeee" | [http://www.ebi.ac.uk/cgi-bin/imgt/hla/get_allele.cgi?DRB1*0304 DRB1*03:04] | |
| bgcolor="#e7dcc3" | EBI-HLA
| bgcolor="#eeeeee" | [http://www.ebi.ac.uk/cgi-bin/imgt/hla/get_allele.cgi?DRB1*0305 DRB1*03:05] {{Webarchive|url=https://web.archive.org/web/20070926223747/http://www.ebi.ac.uk/cgi-bin/imgt/hla/get_allele.cgi?DRB1*0305 |date=2007-09-26 }} | |
| colspan="2" bgcolor="#dddddd" | Shared data | |
| bgcolor="#e7dcc3" | Locus
| bgcolor="#eeeeee" | chr.6 [https://www.ncbi.nlm.nih.gov/Omim/getmap.cgi?chromosome=6p21.31 6p21.31] |
HLA-DR3 is composed of the HLA-DR17 and HLA-DR18 split 'antigens' serotypes. DR3 is a component gene-allele of the AH8.1 haplotype in Northern and Western Europeans. Genes between B8 and DR3 on this haplotype are frequently associated with autoimmune disease. Type 1 diabetes mellitus is associated with HLA-DR3 or HLA-DR4. Nearly half the US population has either DR3 or DR4 (only 1–3% have both), yet only a small percentage (about 0.5%) of these individuals will develop type 1 diabetes.
Serology
| border="0" cellspacing="0" cellpadding="0" align="center" style="text-align:center; background:#ffffff; margin-right: 1em; border:2px #e0e0ff solid;"
|+ DR17 and DR3 recognition of some DRB1*03 alleles[http://www.ebi.ac.uk/imgt/hla/allele.html derived from IMGT/HLA] | ||||
| style="background:#f0f0ff"
| style="width:60px" | DRB1* | style="width:60px" | DR3
| style="width:60px" | DR17 | style="width:60px" | DR18 | style="width:60px" | Sample | |
| style="background:#f0f0ff"
| allele | % | % | % | size (N) |
| style="background:#e8e8f8" | 03:01 | 33 | 64 | 0 | 9698 |
| style="background:#e8e8f8" | 03:02 | 24 | 3 | 66 | 317 |
| style="background:#e8e8f8" | 03:03 | 40 | 60 | 5 | |
| style="background:#e8e8f8" | 03:04 | 60 | 20 | 5 | |
| style="background:#e8e8f8" | 03:07 | >50 | 1 |
Some DR3 also react with HLA-DR17 and/or HLA-DR18. The DRB1*03:04 primarily reacts with DR3. The serotypes of *03:05, *03:06, *03:08 to *03:31 are unknown.
Disease associations
{{further|HLA A1-B8-DR3-DQ2#Importance to Medicine}}
=By serotype=
HLA-DR3 is associated with early-age onset myasthenia gravis, Hashimoto's thyroiditis (along with DR5), primary sclerosing cholangitis,{{cite journal |author=Wiencke K |title=Primary sclerosing cholangitis is associated with extended HLA-DR3 and HLA-DR6 haplotypes |journal=Tissue Antigens |volume=69 |issue=2 |pages=161–9 |year=2007 |pmid=17257319 |doi=10.1111/j.1399-0039.2006.00738.x | author2=Karlsen TH |author3=Boberg KM |last4=Thorsby |first4=E. |last5=Schrumpf |first5=E. |last6=Lie |first6=B. A. |last7=Spurkland |first7=A.}} and opportunistic infections in AIDS,{{cite journal |vauthors=Pollack MS, Gold J, Metroka CE, Safai B, Dupont B |title=HLA-A,B,C and DR antigen frequencies in acquired immunodeficiency syndrome (AIDS) patients with opportunistic infections |journal=Hum. Immunol. |volume=11 |issue=2 |pages=99–103 |year=1984 |pmid=6333416 |doi =10.1016/0198-8859(84)90048-X }} but lowered risk for cancers.{{cite journal |vauthors=Mann DL, Murray C, O'Donnell M, Blattner WA, Goedert JJ |title=HLA antigen frequencies in HIV-1-related Kaposi's sarcoma |journal=J. Acquir. Immune Defic. Syndr. |volume=3 |pages=S51–5 |year=1990 |issue=Suppl 1 |pmid=2395088 }} It is also associated with membranous glomerulonephritis{{Cite book|title=Quick Reference Guide to Medicine and Surgery|last=Weil|first=Leonora|publisher=Mosby: Elsevier|year=2014|isbn=978-0-7234-3553-2|location=Edinburgh|pages=287}}
=By allele=
DRB1*03:01 (see HLA-DR17)
DRB1*03:02 (See HLA-DR18)
DRB1*03:04 is associated with Graves disease{{cite journal |pmid=10468973 |date=Jul 1999 |author1=Heward, Jm |author2=Allahabadia, A |author3=Sheppard, Mc |author4=Barnett, Ah |author5=Franklyn, Ja |author6=Gough, Sc |title=Association of the large multifunctional proteasome (LMP2) gene with Graves' disease is a result of linkage disequilibrium with the HLA haplotype DRB1*0304-DQB1*02-DQA1*0501 |volume=51 |issue=1 |pages=115–8 |issn=0300-0664 |journal=Clinical Endocrinology |doi=10.1046/j.1365-2265.1999.00755.x|s2cid=6376169 }}
=By haplotypes=
DR3 and/or DQ2 is associated with Moreen's ulceration,{{cite journal |vauthors=Taylor C, Smith S, Morgan C, Stephenson S, Key T, Srinivasan M, Cunningham E, Watson P |title=HLA and Mooren's ulceration |journal=Br J Ophthalmol |volume=84 |issue=1 |pages=72–5 |year=2000 |pmid=10611103 |doi=10.1136/bjo.84.1.72 |pmc=1723219}} "bout onset" multiple sclerosis,{{cite journal |vauthors=Weinshenker B, Santrach P, Bissonet A, McDonnell S, Schaid D, Moore S, Rodriguez M |title=Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study |journal=Neurology |volume=51 |issue=3 |pages=742–7 |year=1998 |pmid=9748020 |doi=10.1212/wnl.51.3.742|s2cid=11416838 }} Graves' disease{{cite journal |vauthors=Ratanachaiyavong S, Lloyd L, Darke C, McGregor A |title=MHC-extended haplotypes in families of patients with Graves' disease |journal=Hum Immunol |volume=36 |issue=2 |pages=99–111 |year=1993 |pmid=8096501 |doi=10.1016/0198-8859(93)90112-E}} and systemic lupus erythematosus{{cite journal |vauthors=Tjernström F, Hellmer G, Nived O, Truedsson L, Sturfelt G |title=Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17,DQ2) in determining susceptibility to systemic lupus erythematosus |journal=Lupus |volume=8 |issue=2 |pages=103–8 |year=1999 |pmid=10192503 |doi=10.1191/096120399678847560|s2cid=26486050 }}
DR3-DQ2 linkage is associated with coeliac disease, dermatitis herpetiformis, Diabetes mellitus type 1. DR3-DQ2 is the serological marker for HLA-DQ2.5cis isoform. Although it cannot identify the alpha ".5" chain of HLA DQ, DQA1*05:01 gene is almost always found within the DR3-DQ2 haplotype Eurasia (however in older studies DQA1*05:05 is commonly confused with DQA1*05:01)
{{cite journal |vauthors=Pera C, Delfino L, Longo A, Pistillo MP, Ferrara GB |title=Novel associations among HLA-DQA1 and -DQB1 alleles, revealed by high-resolution sequence-based typing (SBT) |journal=Tissue Antigens |volume=55 |issue=3 |pages=275–9 |date=March 2000 |pmid=10777105 |doi=10.1034/j.1399-0039.2000.550313.x |url=https://zenodo.org/record/1231460 }}